See more : IZOBLOK S.A. (IZB.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Diurnal Group plc (DNL.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Diurnal Group plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Hemostemix Inc. (HMTXF) Income Statement Analysis – Financial Results
- AVer Information Inc. (3669.TW) Income Statement Analysis – Financial Results
- Pingdingshan Tianan Coal. Mining Co., Ltd. (601666.SS) Income Statement Analysis – Financial Results
- PT Garda Tujuh Buana Tbk (GTBO.JK) Income Statement Analysis – Financial Results
- TransGlobe Energy Corporation (TGL.TO) Income Statement Analysis – Financial Results
Diurnal Group plc (DNL.L)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.diurnal.co.uk
About Diurnal Group plc
Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers an oral formulation of hydrocortisone granules in capsules for the treatment of pediatric adrenal insufficiency. It also develops Chronocort, which completed Phase II clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early-stage pipeline products comprise Ditest, a native oral testosterone product, which has completed phase I clinical trial for the treatment of classical hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (triiodothyronine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.68M | 4.37M | 6.31M | 1.04M | 73.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.02M | 779.00K | 668.00K | 224.00K | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.66M | 3.59M | 5.65M | 820.00K | 58.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 78.16% | 82.18% | 89.42% | 78.54% | 79.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.10M | 6.92M | 4.63M | 8.69M | 10.02M | 8.34M | 3.89M | 1.21M | 904.00K |
| General & Administrative | 3.69M | 3.06M | 2.90M | 6.66M | 6.81M | 3.73M | 3.11M | 384.00K | 311.00K |
| Selling & Marketing | 6.72M | 5.24M | 4.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.41M | 8.29M | 7.04M | 6.66M | 6.81M | 3.73M | 3.11M | 384.00K | 311.00K |
| Other Expenses | 109.00K | -15.00K | -627.00K | 0.00 | 0.00 | -9.00K | 0.00 | -661.00K | -336.00K |
| Operating Expenses | 22.62M | 15.19M | 11.04M | 15.35M | 16.84M | 12.07M | 6.99M | 937.00K | 879.00K |
| Cost & Expenses | 23.64M | 15.97M | 11.71M | 15.57M | 16.85M | 12.07M | 6.99M | 937.00K | 879.00K |
| Interest Income | 0.00 | 62.00K | 114.00K | 130.00K | 95.00K | 182.00K | 63.00K | 1.00K | 1.00K |
| Interest Expense | -11.00K | 0.00 | 0.00 | 0.00 | 221.00K | 272.00K | 133.00K | 2.00K | 3.00K |
| Depreciation & Amortization | 158.00K | 24.00K | 25.00K | 22.00K | 14.00K | 7.00K | 6.00K | 6.00K | 6.00K |
| EBITDA | -18.82M | -11.51M | -5.25M | -14.37M | -16.67M | -11.88M | -6.92M | -973.00K | -872.00K |
| EBITDA Ratio | -401.77% | -263.42% | -83.21% | -1,376.82% | -22,835.62% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -18.98M | -11.54M | -5.28M | -14.40M | -16.68M | -11.88M | -6.93M | -979.00K | -878.00K |
| Operating Income Ratio | -405.15% | -263.97% | -83.61% | -1,378.93% | -22,854.79% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.00K | 0.00 | 0.00 | 0.00 | -221.00K | -272.00K | -133.00K | -2.00K | -3.00K |
| Income Before Tax | -18.97M | -11.54M | -5.28M | -14.40M | -16.91M | -12.16M | -7.06M | -981.00K | -881.00K |
| Income Before Tax Ratio | -404.91% | -263.97% | -83.61% | -1,378.93% | -23,157.53% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.40M | -1.49M | -1.21M | -2.11M | -2.28M | -2.73M | -491.00K | -97.00K | -20.00K |
| Net Income | -16.57M | -10.05M | -4.07M | -12.29M | -14.62M | -9.43M | -6.57M | -884.00K | -861.00K |
| Net Income Ratio | -353.76% | -229.90% | -64.50% | -1,177.01% | -20,031.51% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.10 | -0.11 | -0.04 | -0.20 | -0.27 | -0.18 | -0.15 | -0.02 | -0.02 |
| EPS Diluted | -0.10 | -0.11 | -0.04 | -0.20 | -0.27 | -0.18 | -0.15 | -0.02 | -0.02 |
| Weighted Avg Shares Out | 168.71M | 95.23M | 95.33M | 62.46M | 55.18M | 52.79M | 44.21M | 52.77M | 52.77M |
| Weighted Avg Shares Out (Dil) | 169.18M | 95.23M | 95.33M | 62.46M | 55.18M | 52.79M | 44.21M | 52.77M | 52.77M |
Source: https://incomestatements.info
Category: Stock Reports